PAHC RSI Chart
Last 7 days
5.4%
Last 30 days
33.9%
Last 90 days
50.4%
Trailing 12 Months
24.6%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 999.6M | 0 | 0 | 0 |
2023 | 978.1M | 977.9M | 976.7M | 982.0M |
2022 | 907.3M | 942.3M | 960.1M | 972.1M |
2021 | 799.0M | 833.4M | 852.8M | 879.4M |
2020 | 818.4M | 800.4M | 805.8M | 798.0M |
2019 | 835.9M | 828.0M | 817.6M | 813.4M |
2018 | 803.0M | 820.0M | 826.7M | 839.1M |
2017 | 758.6M | 764.3M | 769.7M | 784.0M |
2016 | 747.3M | 751.5M | 752.4M | 752.2M |
2015 | 747.3M | 748.6M | 748.3M | 751.3M |
2014 | 672.4M | 691.9M | 717.1M | 733.1M |
2013 | 653.4M | 653.2M | 653.3M | 661.9M |
2012 | 0 | 654.1M | 653.9M | 653.6M |
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index
Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>
Returns of $10,000 invested in:
Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224
Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Aug 30, 2021 | corcoran e thomas | bought | 118,400 | 23.68 | 5,000 | - |
Feb 09, 2021 | miller larry lee | sold | -458,812 | 22.9406 | -20,000 | chief operating officer |
Feb 08, 2021 | miller larry lee | acquired | - | - | 50,000 | chief operating officer |
Aug 30, 2019 | corcoran e thomas | bought | 106,050 | 21.21 | 5,000 | - |
Jan 30, 2019 | bendheim daniel m | acquired | 28,273 | 11.83 | 2,390 | exec. vp, corporate strategy |
Jan 30, 2019 | bendheim daniel m | sold | -74,448 | 31.15 | -2,390 | exec. vp, corporate strategy |
Jan 29, 2019 | bendheim daniel m | acquired | 57,848 | 11.83 | 4,890 | exec. vp, corporate strategy |
Jan 29, 2019 | bendheim daniel m | sold | -153,155 | 31.32 | -4,890 | exec. vp, corporate strategy |
Jan 28, 2019 | bendheim daniel m | acquired | 29,575 | 11.83 | 2,500 | exec. vp, corporate strategy |
Jan 28, 2019 | bendheim daniel m | sold | -78,875 | 31.55 | -2,500 | exec. vp, corporate strategy |
Which funds bought or sold PAHC recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 07, 2024 | SEI INVESTMENTS CO | reduced | - | 236,593 | 2,266,660 | -% |
May 07, 2024 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | added | 10.87 | 37,800 | 196,678 | -% |
May 07, 2024 | Swiss National Bank | unchanged | - | 54,135 | 518,493 | -% |
May 07, 2024 | NEW YORK STATE COMMON RETIREMENT FUND | added | 0.4 | 57,000 | 527,000 | -% |
May 07, 2024 | Illinois Municipal Retirement Fund | added | 7.17 | 24,000 | 148,000 | -% |
May 06, 2024 | SG Americas Securities, LLC | sold off | -100 | -121,000 | - | -% |
May 06, 2024 | LSV ASSET MANAGEMENT | unchanged | - | 147,000 | 1,402,000 | -% |
May 06, 2024 | TEXAS PERMANENT SCHOOL FUND CORP | added | 1.61 | 26,786 | 225,835 | -% |
May 06, 2024 | Parallel Advisors, LLC | sold off | -100 | -753 | - | -% |
May 06, 2024 | TEACHER RETIREMENT SYSTEM OF TEXAS | new | - | 219,000 | 219,000 | -% |
Unveiling Phibro Animal Health Corp's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Phibro Animal Health Corp)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 358.5B | 85.6B | 9.32 | 4.19 | ||||
MRK | 328.0B | 61.4B | 142.26 | 5.34 | ||||
AMGN | 164.9B | 29.5B | 43.82 | 5.58 | ||||
PFE | 160.3B | 57.8B | 127.84 | 2.77 | ||||
GILD | 80.9B | 27.4B | 166.89 | 2.95 | ||||
TEVA | 17.8B | 16.0B | -36.03 | 1.11 | ||||
MID-CAP | ||||||||
PRGO | 4.2B | 4.6B | -550.77 | 0.93 | ||||
ALKS | 4.1B | 1.7B | 9.39 | 2.36 | ||||
BHC | 2.6B | 9.0B | -5.66 | 0.29 | ||||
AMPH | 2.0B | 644.4M | 14.77 | 3.15 | ||||
SMALL-CAP | ||||||||
TLRY | 1.5B | 743.2M | -4.27 | 2.02 | ||||
TXMD | 23.3M | 1.3M | -2.27 | 17.89 | ||||
ACRX | 17.5M | - | -0.95 | 0.22 | ||||
AGRX | 2.7M | 19.6M | -0.19 | 0.14 | ||||
ACOR | 1.1M | 117.6M | 0 | 0.01 |
Phibro Animal Health Corp News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | 5.3% | 263 | 250 | 231 | 255 | 246 | 245 | 233 | 255 | 240 | 233 | 215 | 220 | 212 | 206 | 195 | 186 | 211 | 214 | 190 | 204 | 206 |
Gross Profit | 1.3% | 80.00 | 79.00 | 68.00 | 77.00 | 76.00 | 77.00 | 69.00 | 78.00 | 72.00 | 71.00 | 65.00 | 70.00 | 69.00 | 68.00 | 64.00 | 61.00 | 70.00 | 69.00 | 58.00 | 65.00 | 65.00 |
S&GA Expenses | -5.1% | 60.00 | 63.00 | 68.00 | 53.00 | 57.00 | 62.00 | 55.00 | 56.00 | 52.00 | 48.00 | 50.00 | 51.00 | 49.00 | 48.00 | 48.00 | 42.00 | 48.00 | 49.00 | 48.00 | 53.00 | 42.00 |
EBITDA Margin | -6.5% | 0.04* | 0.05* | 0.06* | 0.07* | 0.07* | 0.08* | 0.09* | 0.10* | 0.11* | 0.10* | 0.09* | 0.10* | 0.11* | 0.11* | 0.11* | 0.09* | 0.08* | 0.08* | 0.08* | 0.11* | 0.12* |
Interest Expenses | 1.8% | -4.57 | -4.66 | -4.56 | -4.50 | -3.87 | -3.88 | -3.07 | -3.11 | -2.92 | -2.95 | -2.89 | -3.92 | -2.93 | -3.21 | -2.81 | -2.81 | -3.26 | -3.43 | -3.35 | -3.05 | -2.93 |
Income Taxes | 97.2% | 5.00 | 2.00 | -3.96 | 10.00 | 5.00 | 5.00 | 2.00 | 5.00 | 9.00 | 6.00 | 3.00 | -1.00 | 6.00 | 3.00 | 4.00 | 11.00 | 5.00 | 5.00 | 1.00 | 0.00 | 5.00 |
Earnings Before Taxes | 262.5% | 13.00 | 4.00 | -11.98 | 21.00 | 15.00 | 12.00 | 5.00 | 12.00 | 27.00 | 24.00 | 10.00 | 16.00 | 18.00 | 16.00 | 17.00 | 16.00 | 19.00 | 17.00 | 4.00 | 9.00 | 20.00 |
EBT Margin | -9.4% | 0.03* | 0.03* | 0.04* | 0.06* | 0.05* | 0.06* | 0.07* | 0.08* | 0.08* | 0.08* | 0.07* | 0.08* | 0.08* | 0.08* | 0.08* | 0.07* | 0.06* | 0.06* | 0.06* | 0.09* | 0.10* |
Net Income | 559.7% | 8.00 | 1.00 | -4.66 | 11.00 | 10.00 | 7.00 | 5.00 | 14.00 | 18.00 | 11.00 | -0.36 | 13.00 | 12.00 | 25.00 | 8.00 | 8.00 | 14.00 | 15.00 | -5.03 | 11.00 | 15.00 |
Net Income Margin | -10.9% | 0.02* | 0.02* | 0.02* | 0.03* | 0.04* | 0.05* | 0.05* | 0.05* | 0.05* | 0.04* | 0.06* | 0.07* | 0.07* | 0.07* | 0.06* | 0.04* | 0.04* | 0.04* | 0.05* | 0.06* | 0.08* |
Free Cashflow | -63.9% | 11.00 | 32.00 | 16.00 | 20.00 | 6.00 | -2.49 | -10.70 | 2.00 | 6.00 | 20.00 | 4.00 | 3.00 | 17.00 | 27.00 | 2.00 | 4.00 | 27.00 | 32.00 | -3.57 | 15.00 | 16.00 |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | 0.7% | 979 | 973 | 965 | 971 | 965 | 962 | 948 | 932 | 916 | 849 | 836 | 841 | 805 | 804 | 790 | 784 | 776 | 788 | 795 | 727 | 706 |
Current Assets | 1.8% | 597 | 587 | 584 | 586 | 585 | 582 | 570 | 566 | 546 | 509 | 499 | 499 | 472 | 477 | 464 | 452 | 438 | 445 | 456 | 466 | 452 |
Cash Equivalents | 52.3% | 50.00 | 33.00 | 43.00 | 41.00 | 37.00 | 68.00 | 76.00 | 74.00 | 71.00 | 63.00 | 41.00 | 50.00 | 49.00 | 35.00 | 31.00 | 36.00 | 27.00 | 26.00 | 55.00 | 58.00 | 36.00 |
Inventory | -1.5% | 282 | 287 | 279 | 278 | 293 | 289 | 281 | 259 | 250 | 231 | 221 | 216 | 206 | 213 | 206 | 197 | 177 | 194 | 204 | 198 | 190 |
Net PPE | 0.6% | 202 | 201 | 193 | 196 | 189 | 186 | 179 | 165 | 162 | 155 | 153 | 155 | 150 | 150 | 147 | 148 | 143 | 145 | 142 | 140 | 135 |
Goodwill | -0.1% | 55.00 | 55.00 | 53.00 | 53.00 | 53.00 | 53.00 | 53.00 | 53.00 | 53.00 | 53.00 | 53.00 | 53.00 | 53.00 | 53.00 | 53.00 | 53.00 | 53.00 | 53.00 | 53.00 | 27.00 | 27.00 |
Liabilities | 1.0% | 709 | 702 | 691 | 689 | 693 | 693 | 686 | 669 | 649 | 610 | 603 | 603 | 589 | 590 | 597 | 596 | 581 | 571 | 589 | 511 | 493 |
Current Liabilities | 0.7% | 189 | 188 | 172 | 176 | 165 | 168 | 172 | 191 | 187 | 167 | 153 | 164 | 169 | 167 | 161 | 157 | 161 | 147 | 142 | 154 | 133 |
Long Term Debt | - | 291 | - | - | 312 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 218 | 221 |
Shareholder's Equity | -0.3% | 270 | 271 | 273 | 283 | 272 | 268 | 263 | 262 | 267 | 239 | 233 | 239 | 216 | 213 | 192 | 188 | 195 | 217 | 207 | 216 | 214 |
Retained Earnings | 1.5% | 248 | 244 | 248 | 261 | 254 | 249 | 247 | 248 | 245 | 232 | 220 | 218 | 206 | 198 | 191 | 183 | 182 | 174 | 167 | 169 | 165 |
Additional Paid-In Capital | 0.1% | 136 | 136 | 136 | 136 | 136 | 136 | 136 | 136 | 136 | 136 | 136 | 136 | 137 | 137 | 136 | 136 | 135 | 134 | 134 | 133 | 133 |
Shares Outstanding | 0% | 41.00 | 41.00 | 41.00 | 41.00 | 41.00 | 41.00 | 41.00 | 41.00 | 41.00 | 41.00 | 41.00 | 40.00 | 40.00 | 40.00 | 40.00 | 40.00 | 40.00 | 40.00 | 40.00 | - | 40.00 |
Float | - | - | - | - | - | - | 272 | - | - | - | 414 | - | - | - | 393 | - | - | - | 502 | - | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -63.9% | 11,408 | 31,558 | 16,199 | 20,238 | 6,259 | -2,489 | -10,698 | 1,574 | 6,132 | 20,122 | 3,821 | 3,070 | 16,625 | 26,913 | 1,698 | 3,877 | 26,950 | 32,091 | -3,570 | 14,879 | 15,654 |
Share Based Compensation | 68.8% | 135 | 80.00 | 81.00 | - | - | - | - | - | - | - | - | - | - | 564 | 565 | 565 | 565 | 564 | 565 | 565 | 565 |
Cashflow From Investing | 104.5% | 1,130 | -24,861 | -15,352 | -10,282 | -37,777 | -9,810 | -16,149 | -9,540 | -9,944 | 17,568 | -20,666 | -7,190 | 9,869 | -7,624 | -13,635 | -9,533 | -14,148 | -34,178 | -62,531 | 14,743 | -7,948 |
Cashflow From Financing | 133.0% | 4,854 | -14,705 | 1,296 | -6,332 | 284 | 3,716 | 29,319 | 12,389 | 10,265 | -14,576 | 8,265 | 4,637 | -11,548 | -16,542 | 6,458 | 14,985 | -10,979 | -27,001 | 63,931 | -7,999 | -2,982 |
Dividend Payments | -100.0% | - | 4,861 | 4,860 | 4,861 | 4,861 | 4,860 | 4,860 | 4,861 | 4,860 | 4,861 | 4,860 | 4,861 | 4,860 | 4,855 | 4,854 | 4,855 | 4,854 | 4,855 | 4,854 | 4,854 | 4,855 |
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | |
Income Statement [Abstract] | ||||
Net sales | $ 249,943 | $ 244,646 | $ 481,292 | $ 477,167 |
Cost of goods sold | 171,327 | 167,261 | 334,950 | 331,136 |
Gross profit | 78,616 | 77,385 | 146,342 | 146,031 |
Selling, general and administrative expenses | 62,915 | 61,541 | 131,367 | 116,503 |
Operating income | 15,701 | 15,844 | 14,975 | 29,528 |
Interest expense, net | 4,659 | 3,884 | 9,223 | 6,951 |
Foreign currency losses (gains), net | 7,477 | (149) | 14,166 | 5,051 |
Income (loss) before income taxes | 3,565 | 12,109 | (8,414) | 17,526 |
Provision (benefit) for income taxes | 2,291 | 4,899 | (1,673) | 6,460 |
Net income (loss) | $ 1,274 | $ 7,210 | $ (6,741) | $ 11,066 |
Net income (loss) per share | ||||
basic (in dollars per share) | $ 0.03 | $ 0.18 | $ (0.17) | $ 0.27 |
diluted (in dollars per share) | $ 0.03 | $ 0.18 | $ (0.17) | $ 0.27 |
Weighted average common shares outstanding | ||||
basic (in shares) | 40,504 | 40,504 | 40,504 | 40,504 |
diluted (in shares) | 40,504 | 40,504 | 40,504 | 40,504 |
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2023 | Jun. 30, 2023 |
---|---|---|
ASSETS | ||
Cash and cash equivalents | $ 32,970 | $ 41,281 |
Short-term investments | 59,523 | 40,000 |
Accounts receivable, net | 150,627 | 163,479 |
Inventories, net | 286,680 | 277,570 |
Other current assets | 56,786 | 63,393 |
Total current assets | 586,586 | 585,723 |
Property, plant and equipment, net | 200,839 | 195,568 |
Intangibles, net | 50,962 | 54,987 |
Goodwill | 54,683 | 53,274 |
Other assets | 79,638 | 81,845 |
Total assets | 972,708 | 971,397 |
LIABILITIES AND STOCKHOLDERS' EQUITY | ||
Current portion of long-term debt | 26,045 | 22,295 |
Accounts payable | 86,410 | 73,853 |
Accrued expenses and other current liabilities | 75,280 | 79,852 |
Total current liabilities | 187,735 | 176,000 |
Revolving credit facility | 151,000 | 141,000 |
Long-term debt | 297,853 | 311,541 |
Other liabilities | 65,317 | 60,347 |
Total liabilities | 701,905 | 688,888 |
Commitments and contingencies (Note 8) | ||
Common stock, par value $0.0001 per share; 300,000,000 Class A shares authorized, 20,337,574 shares issued and outstanding at December 31, 2023, and June 30, 2023; 30,000,000 Class B shares authorized, 20,166,034 shares issued and outstanding at December 31, 2023, and June 30, 2023 | 4 | 4 |
Preferred stock, par value $0.0001 per share; 16,000,000 shares authorized, no shares issued and outstanding | ||
Paid-in capital | 135,964 | 135,803 |
Retained earnings | 244,450 | 260,912 |
Accumulated other comprehensive loss | (109,615) | (114,210) |
Total stockholders' equity | 270,803 | 282,509 |
Total liabilities and stockholders' equity | $ 972,708 | $ 971,397 |
 | Mr. Jack Clifford Bendheim |
---|---|
 | pahc.com |
 | Pharmaceuticals |
 | 1920 |